Febuxostat 80 mg Tablet Febucip

Febuxostat 80mg Tablet is a medicine primarily used to treat gout, a type of arthritis caused by excess uric acid in the blood. It works by lowering uric acid levels, thereby preventing gout attacks.

• Management of chronic hyperuricemia in situations where urate deposition has already occurred.
• Treatment and prevention of gout attacks.

Febuxostat 80mg Tablet is a xanthine oxidase inhibitor. It works by inhibiting an enzyme called xanthine oxidase, which is responsible for converting hypoxanthine to xanthine and xanthine to uric acid, thereby decreasing the levels of uric acid in the blood.

The usually recommended dose is 80 mg once daily. Depending on the patient’s uric acid levels, the dose may be adjusted.

• Common side effects include abnormalities in liver function, nausea, joint pain, and rash.
• Serious side effects may include cardiovascular events such as heart attack or stroke and severe skin reactions.

• Regular liver function tests are recommended during treatment.
• Patients with severe kidney disease are advised not to take this drug without medical advice.
• Patients with a history of cardiac diseases are advised to exercise caution.

• Febuxostat 80mg Tablet may interact with azathioprine, mercaptopurine, and theophylline, causing potential toxicity.
• Patients should inform their healthcare provider about all medications they are taking.

• Store in a cool, dry place away from direct sunlight and moisture.
• Keep out of reach of children.

Febuxostat 80 mg Tablet is an important drug in the management of gout, helping patients by effectively reducing uric acid levels and preventing painful gout attacks. Proper use and regular monitoring can ensure its efficacy and safety.

Check this Product Arthritis Adalimumab 40 mg Injection Plamumab or you may explore more Arthritis clicking here

We are an exporter from India and work in excess countries like the UAE , Oman, Qatar, Myanmar, Saudi Arabia, Netherland, Albania, Saint lucia , Jordan , Romania ,South africa , and so on.